Ibrutinib + Chemoimmunotherapy (Cit) for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-Nhl) in Children (Sparkle Trial): Initial Safety, Pk, and Efficacy
Hematological Oncology - United Kingdom
doi 10.1002/hon.27_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley